AUTHOR SUMMARY
The potential to kill cancer cells selectively via apoptosis, or programmed cell death, is recognized as a highly valuable therapeutic strategy. However, because of the inherent signaling complexities of cancer cells, simultaneous activation of multiple components of apoptotic pathways is likely required to achieve effective treatment. We screened an entire genome using an RNAi approach and identified several novel regulators of death receptor-mediated apoptosis. Two of these regulators inhibit the expression of cell surface receptors involved in apoptosis and are frequently amplified in cancer. Collectively, our findings highlight a mechanism by which cancer cells may evade apoptosis and provide insights into the search for targets and functional biomarkers for the receptor-mediated apoptotic pathway.
Our screen focused on the apoptotic pathway activated via cell surface receptors commonly referred to as the extrinsic signaling pathway. This apoptotic pathway is induced by small signaling molecules called ligands that bind to the cell surface receptors, aptly named "death receptors." The appropriate ligand binds to its corresponding death receptor, which initiates a signaling cascade that eventually activates the molecules that carry out apoptosis (1, 2) . With the aim of uncovering novel strategies to activate death receptor-mediated apoptosis in cancer cells selectively, we searched for genes that regulate the sensitivity to death receptor ligands.
We screened the human genome by using shRNAs that can selectively turn off or silence targeted genes. We delivered these shRNAs into the cells using Lentivirus as the vector (3). We first divided the shRNA library into two viral pools, each consisting of ∼35,000 shRNAs. A common cell line known as fibrosarcoma HT1080 was treated with each shRNA pool. This was followed by treatment with one of the important ligands in death receptor-mediated apoptosis, the FAS ligand (FASL). Nine days following the initial FASL treatment, the shRNAs integrated into target cell DNA were recovered by PCR amplification. The change in shRNA representation between the FASL-treated and control cells was quantified using two different methods to overcome the bias introduced by each of these procedures (Fig. P1A) .
To remove erroneous hits resulting from a common problem known as an off-target RNAi effect, we performed a series of validation experiments. First, we retested the top ∼250 hits as individual shRNAs. Second, we repeated the treatment with FASL for the top hits by using siRNAs, which also act as an RNAi trigger. For the tertiary-level validation, five hits, PTK7, UNC13D, TAOK2, EDD1, and GRHL2, were selected based on the finding that they exhibit frequent overexpression and/or copy number gain in cancer. We retested each of these hits with four different siRNAs for each gene and looked for increased FASL sensitivity with at least two independent siRNAs. This method identified the three top hits: PTK7, EDD1, and GRHL2.
We next investigated the mechanism of how these top three hits regulate FASL-mediated apoptosis. For this purpose, we silenced each gene to determine if they modulate the expression of death receptors. Somewhat surprisingly, we found that silencing each gene induced a two-to fourfold increase in the mRNA levels of a receptor called FAS. A similar impact on the mRNA levels of a related death receptor, DR5, was also observed upon silencing EDD1 and GRHL2, whereas silencing PTK7 exhibited little or no effect on DR5 expression. In contrast, there was little or no induction of another death receptor, TNFR1, when any of the three genes were silenced. Thus, all the top three hits modulated the expression of the FAS receptor, which is the likely mechanism by which silencing of PTK7, EDD1, or GRHL2 sensitizes cells to FASL. Interestingly, PTK7 exhibits the greatest specificity for regulating the FAS receptor, whereas EDD1 and GRHL2 regulate the expression of both FAS and DR5 receptors. We focused further experiments on two genes with the most therapeutic potential by first inspecting their genomic and expression data in closer detail. Interestingly, we found that both genes localize to a genomic region on chromosome 8q22, one already implicated in multiple cancers. Using GISTIC, an algorithm for quantifying chromosomal copy number changes (4), we found that both GRHL2 and EDD1 localize within a large region on chromosome 8q frequently amplified in breast (Fig. P1B) , lung, melanoma, and ovarian cancers. Importantly, the genomic amplification correlated well with the expression level for both EDD1 and GRHL2. We then used FACS and Western blot analyses to measure the impact on death receptor expression following silencing of EDD1 and GRHL2. Upon silencing of either gene, FAS (Fig. P1C ) and DR5 protein levels were induced, indicating negative regulation of death receptor activity. Given that our functional data implicate a role for EDD1 and GRHL2 in suppressing death receptor-mediated apoptosis, we hypothesized that amplification of either gene could contribute to a mechanism by which cancer cells evade therapeutic challenge with death receptor agonists. To address this question, we interrogated previously published gene expression profiles of cancer cells resistant to a proapoptotic receptor agonist, dulanermin (5). Studies on dulanermin-resistant pancreatic, breast, and lung cancer cell lines supported our hypothesis that these genes confer resistance to targeted apoptosis, particularly EDD1. The expression of EDD1 is elevated in these cancer cell lines, which was quantitatively confirmed. We did not find a statistically significant difference in GRHL2 expression between dulanermin-sensitive and -resistant cell lines. However, we were able to confirm elevated EDD1 and GRHL2 protein expression in several dulanermin-resistant breast cancer cell lines exhibiting copy number gains at the 8q22 locus. The functional relevance for the 8q22 gene cluster at contributing to resistance of cancer cells to death receptor agonists was tested directly by quantifying the effect of silencing EDD1 or GRHL2 in dulanermin-resistant breast cancer cell lines. We found that silencing EDD1 or GRHL2 sensitized four breast cancer cell lines with amplified 8q22 to dulanermin-induced apoptosis; this correlated with the degree of EDD1 and GRHL2 silencing as well as with a corresponding induction of DR5 expression.
Our results point the way to novel strategies for sensitizing cancer cells to death receptor-mediated apoptosis. Mechanistically, we found that both EDD1 and GRHL2 inhibit death receptor-mediated apoptosis by repressing the expression of death receptors FAS and DR5 (Fig. P1D) . Furthermore, EDD1 expression is elevated in cancer cell lines classified as resistant to death receptor-mediated apoptosis and is consistent with our finding that silencing either EDD1 or GRHL2 sensitizes resistant breast cancer cells to ligand-induced apoptosis. Therefore, the identification of EDD1 and GRHL2 raises the possibility that targeting their activity or expression would provide a therapeutically relevant strategy in improving cancer cell responsiveness to death receptor-mediated apoptosis. These findings are significant because they describe a unique mechanism for regulating apoptosis and highlight potential therapeutic strategies for activating apoptosis in cancer.
